| Literature DB >> 28452165 |
M Ilyas1, O R Colegio2, B Kaplan3, A Sharma1.
Abstract
Despite the abundance of information on cutaneous malignancies associated with solid organ transplantation in the transplant literature, there is limited information regarding nonmalignant skin changes after transplantation. There are numerous skin toxicities secondary to immunosuppressive and other transplant-related medications that can vary in presentation, severity, and prognosis. To limit associated morbidity and mortality, solid organ transplant recipient care providers should effectively identify and manage cutaneous manifestations secondary to drug toxicity. Toxicities from the following transplant-related medications will be discussed: antithymocyte globulins, systemic steroids, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mammalian target of rapamycin inhibitors sirolimus and everolimus, basiliximab and daclizumab, belatacept, and voriconazole.Entities:
Keywords: clinical research/practice; complication; dermatology; drug toxicity; health services and outcomes research; immunosuppressant; immunosuppression/immune modulation; pharmacology
Mesh:
Substances:
Year: 2017 PMID: 28452165 DOI: 10.1111/ajt.14337
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086